Olema Pharmaceuticals
OLMA
97 hedge funds and large institutions have $584M invested in Olema Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 8 closing their positions.
445% more call options, than puts
Call options by funds: $2.91M | Put options by funds: $534K
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
78% more capital invested
Capital invested by funds: $329M → $584M (+$255M)
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
11% more funds holding
Funds holding: 87 → 97 (+10)
2.93% less ownership
Funds ownership: 89.34% → 86.4% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$41.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$19.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$15.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$14.5M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$10.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.39M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.15M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.01M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$1.64M |
OLMA Hedge Fund Activity: Q3 2023 in Review
97 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q3 2023, worth a combined $584M — up 78% from $329M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new OLMA positions and 8 closed out — a net gain of 10 holders — while 35 added to existing stakes and 31 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $41.5M. The largest seller was Kynam Capital Management, cutting an estimated $10.9M.
- 97 institutional investors held Olema Pharmaceuticals (OLMA) as of Q3 2023, up from 87 in Q2 2023.
- Funds reported $584M of Olema Pharmaceuticals stock for Q3 2023, up 78% quarter-over-quarter.
- 18 funds opened new Olema Pharmaceuticals positions in Q3 2023 and 8 closed out, a net change of +10 holders.
- The largest Olema Pharmaceuticals buyer in Q3 2023 was Paradigm Biocapital Advisors, an estimated $41.5M added.
- The largest Olema Pharmaceuticals seller in Q3 2023 was Kynam Capital Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q3 2023.